Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Hikma Pharmaceuticals PLC
  6. Summary
    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS PLC

(HIK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
2391(c) 2375(c) 2365(c) 2386(c) 2415(c) Last
313 340 290 033 259 685 310 780 544 216 Volume
+0.17% -0.67% -0.42% +0.89% +1.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 506 M - -
Net income 2021 431 M - -
Net Debt 2021 232 M - -
P/E ratio 2021 18,2x
Yield 2021 1,68%
Sales 2022 2 725 M - -
Net income 2022 483 M - -
Net cash position 2022 34,8 M - -
P/E ratio 2022 16,3x
Yield 2022 1,85%
Capitalization 7 658 M 7 662 M -
EV / Sales 2021 3,15x
EV / Sales 2022 2,80x
Nbr of Employees 8 600
Free-Float 67,7%
More Financials
Company
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells... 
More about the company
Ratings of Hikma Pharmaceuticals PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about HIKMA PHARMACEUTICALS PLC
07:30aHIKMA PHARMACEUTICALS : Citigroup Maintains Hikma Pharmaceuticals At Buy, Lifts PT
MT
04:28aEnergy stocks, banks lift FTSE 100; Rolls-Royce top performer
RE
03:18aHIKMA PHARMACEUTICALS : Drugmaker Hikma to buy U.S.-based Custopharm to boost needle-based..
RE
03:03aFTSE 100 Seen Opening Higher
DJ
02:38aHIKMA PHARMACEUTICALS : To Buy US-Based Generics Group Custopharm For $425 Milion
MT
09/23HIKMA PHARMACEUTICALS : Generics Meet the Management Presentation
PU
09/02HIKMA PHARMACEUTICALS : Barclays Boosts Hikma Pharmaceutical PT, Keeps Overweight Rating
MT
08/27HIKMA PHARMACEUTICALS : Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive C..
BU
08/27Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and ..
CI
08/24Today on Wall Street: A new central bank theory
08/24ANALYST RECOMMENDATIONS : M&S, Estee Lauder, Planet Fitness, Snowflake, Steel Dynamics...
08/19HIKMA PHARMACEUTICALS PLC : Ex-dividend day for interim dividend
FA
08/17Energy, healthcare stocks lift FTSE 100; BHP Group shines
RE
08/06London Shares Fall as Investors Await US Jobs Data
DJ
08/06London Shares to Open Slightly Higher as US Jobs Data Eyed
DJ
More news
News in other languages on HIKMA PHARMACEUTICALS PLC
02:38aHikma va racheter le groupe américain de génériques Custopharm pour 425 millions de dol..
08/24STOCK MARKET PARIS : Le verre à moitié plein
08/24AVIS D'ANALYSTES DU JOUR : Adecco, Alcon, Clasquin, Publicis, Vifor, Zurich...
04/28BRUSSELS STOCK EXCHANGE : Brussel sluit in het groen
04/28Ontex herpakt zich op groene beurs
More news
Analyst Recommendations on HIKMA PHARMACEUTICALS PLC
More recommendations
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals PLC Technical Analysis Chart | HIK | GB00B0LCW083 | MarketScreener
Technical analysis trends HIKMA PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 33,09 $
Average target price 38,17 $
Spread / Average Target 15,3%
EPS Revisions
Managers and Directors
Sigurdur Oli Olafsson Chief Executive Officer & Director
Khalid Walid Hosni Nabilsi Chief Financial Officer
Said Samih Taleb Darwazah Executive Chairman
Shahin Fesharaki Chief Scientific Officer
Henriette Nielsen Executive Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
HIKMA PHARMACEUTICALS PLC-4.09%7 549
JOHNSON & JOHNSON3.68%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY34.09%210 037